LLY · News · 20260831N
Acquisition - Merida Biosciences
ELI LILLY & Co · 2026-08-31 · Importance 71 · Surprise 60 · In source text
Eli Lilly agreed to acquire privately held Merida Biosciences for up to $2.88 billion in cash. The transaction adds Merida’s antibody-engineering platform, which is designed to selectively remove disease-causing antibodies while preserving normal immune function. Merida’s lead asset, MER511, has generated initial Phase 1 data showing robust reductions in pathogenic thyroid-stimulating antibodies and a favorable initial safety profile. The acquisition expands Lilly’s immunology and autoimmune/allergic disease pipeline beyond its obesity and diabetes franchises.
Key facts
- Eli Lilly said it would acquire privately held Merida Biosciences for up to $2.88 billion in cash. source
- Eli Lilly has agreed to pay up to $2.875 billion in cash for biotechnology company Merida Biosciences. source
- Eli Lilly and Company announced a definitive agreement for Lilly to acquire Merida Biosciences on Aug. 31, 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | committed | -1.7% | Eli Lilly has agreed to pay up to $2.875 billion in cash for biotechnology company Merida Biosciences. |